Stocks Surge as Strait of Hormuz Reopens, Oil Prices Plunge 
Energy Price Spike Won't Trigger Lasting Inflation, Analysts Say 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Dollar Retreats as Strait of Hormuz Reopens, Easing Safe-Haven Demand 
Morgan Stanley Warns Against Overestimating EV Demand Boost from Rising Oil Prices 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Middle East Ceasefire Hopes Lift Asian Markets as Oil Prices Retreat 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
South Korea's Capital Markets Rebound as Foreign Investors Return 
Want to cut your energy bills? Here’s how five experts are doing it 
LG Chem Ltd. announced it set to buy AVEO Pharmaceuticals for $566 million or $15 per share in full cash. The South Korean chemical company headquartered in Seoul is aiming to purchase a 100% stake in the Boston-based company.
With the acquisition, LG Chem will expand its commercial footprint in the US market for a wide range of oncology therapies. The company also revealed on Tuesday, Oct. 18, that it will also use the deal to branch out to other related fields.
According to The Korea Times, AVEO Pharma developed FOTIVDA prescription medicine made for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC). this drug was only approved in March 2021 by the U.S. Food and Drug Administration (FDA).
LG Chem said that this is the first time that a South Korean company is buying a firm that has been granted approval by the FDA for a new type of drug. As it acquires AVEO, the company is planning to invest in LG Chem Life Science Innovation Center so it can establish a special purpose company for the takeover of the US-based pharma firm.
Moreover, the deal will provide LG Chem’s Life Sciences unit with a commercial presence in the United States. This will also speed up the company’s efforts to deliver its continued growth.
The transaction is expected to close in early 2023, and as with any other buyout deals, this is still subject to customary closing conditions. It should be approved by AVEO’s shareholders and go through regulatory processes.
“With its track record of clinical success, deep pipeline of innovative therapies and continued growth trajectory following the successful commercialization of FOTIVDA, AVEO is the perfect partner for LG Chem Life Sciences,” LG Chem’s chief executive officer, Shin Hak Cheol, said in a press release. “This transaction represents the next step in our portfolio transformation towards higher growth markets and provides a strong commercial foundation in oncology as we continue to develop our anti-cancer offerings.
The CEO further said, “We remain focused on prudently investing in our R&D capabilities, continuing to build a leading portfolio of therapies and transforming lives through inspiring science and leading innovation.”
